This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
gene-therapy: Archive
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
by Zacks Equity Research
Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.
BIIBPositive Net Change FOLDPositive Net Change SRPTNegative Net Change
biotechs earnings gene-therapy medical pharmaceuticals
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
BIIBPositive Net Change VRTXPositive Net Change FOLDPositive Net Change CRSPPositive Net Change
biotechs cell-therapy crispr gene-therapy medical pharmaceuticals
CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.
REGNNegative Net Change PFENegative Net Change VRTXPositive Net Change CRSPPositive Net Change
biotechs cell-therapy crispr earnings gene-therapy medical pharmaceuticals
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
by Zacks Equity Research
Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.
VRTXPositive Net Change ANIPNegative Net Change FATENegative Net Change EDITNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Should You Buy Marriott International (MAR) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MARNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Ardagh Metal Packaging S.A. (AMBP)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
AMBPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Nayax (NYAX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
NYAXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Southwest Airlines (LUV) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
LUVNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
McEwen (MUX) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MUXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SRRKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
REE Automotive Ltd. (REE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
REENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
FOLDPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, HCI Group (HCI)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HCIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
by Zacks Equity Research
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.
PFENegative Net Change BMRNNegative Net Change NVONegative Net Change QUREPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Should You Buy Roku (ROKU) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ROKUNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
by Ahan Chakraborty
Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.
VRTXPositive Net Change CRSPPositive Net Change FULCNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Riot Platforms, Inc. (RIOT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
RIOTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
by Zacks Equity Research
Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.
ALNYNegative Net Change CPRXNegative Net Change ANIPNegative Net Change RARENegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
SoFi Technologies, Inc. (SOFI) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SOFINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
by Zacks Equity Research
Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study.
ANIPNegative Net Change RARENegative Net Change KRYSPositive Net Change FULCNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
ProAssurance (PRA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
PRAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ATATNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Intercorp Financial Services Inc. (IFS)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IFSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Kilroy Realty (KRC)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
KRCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Ball (BALL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BALLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines